Study of KBA1412 in Participants With Advanced Solid Malignant Tumors

NCT05501821 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor Malignancy

Interventions

DRUG: KBA1412
DRUG: Pembrolizumab

Sponsor

Kling Biotherapeutics B.V.